Persistent URL of this record https://hdl.handle.net/1887/18551
Documents
-
- Download
- Front cover
-
open access
-
- Download
- Title page_Table of contents
-
open access
-
- Download
- Chapter 1 Introduction
-
open access
-
- Download
- Chapter 2
-
open access
- Full text at publishers site
-
- Download
- Chapter 3
-
open access
- Full text at publishers site
-
- Download
- Part II Characteristics of ACPA
-
open access
-
- Download
- Chapter 6
-
open access
- Full text at publishers site
-
- Download
- Chapter 7
-
open access
- Full text at publishers site
-
- Download
- Chapter 8
-
open access
- Full text at publishers site
-
- Download
- Chapter 9
-
open access
- Full text at publishers site
-
- Download
- Chapter 10
-
open access
- Full text at publishers site
-
- Download
- Chapter 11
-
open access
- Full text at publishers site
-
- Download
- Chapter 12
-
open access
- Full text at publishers site
-
- Download
- Part III Remission
-
open access
-
- Download
- Chapter 13
-
open access
- Full text at publishers site
-
- Download
- Chapter 14
-
open access
-
- Download
- Chapter 15 Summary and discussion
-
open access
-
- Download
- Chapter 16 Summary in Dutch
-
open access
-
- Download
- Back cover
-
open access
-
- Download
- Propositions
-
open access
In Collections
This item can be found in the following collections:
Anti-citrullinated protein antibodies (ACPA) in rheumatoid arthritis : linking genetic predisposition to clinical outcome
- All authors
- Woude, D. van der
- Supervisor
- Huizinga, T.W.J.; Toes, R.E.M.
- Qualification
- Doctor (dr.)
- Awarding Institution
- Leiden University Medical Center (LUMC) , Leiden University
- Date
- 2012-03-01
- ISBN (print)
- 9789461691439
Funding
- Sponsorship
- The research described in this thesis was supported by ZonMW (AGIKO grant). The printing of this thesis was financially supported by Abbott BV, Euro-Diagnostica, Janssen Biologics BV, the J.E. Jurriaanse foundation, Merck Sharp & Dohme BV, Pfizer BV, Phadia BV, the Dutch Arthritis Association (het Reumafonds), Roche Nederland BV, Teva Pharma BV en UCB Pharma BV.